Saturday 17 October 2026
Export ELAN’s income statement to Excel — free account
Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.55
0.01
+0.04%
Follow ELAN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 5 | 5 | 5 |
| 0.54% | (3.67%) | (3.77%) | (2.98%) | ||
| 0.27% | (1.79%) | (1.85%) | (1.46%) | ||
ROIC |
1.21% | 0.09% | 0.35% | 0.51% | |
Return on Tangible Assets |
1.05% | (7.09%) | (7.30%) | (5.93%) | |
Average Days of Receivables |
77.52 | 72.77 | 86.08 | 83.76 | |
Free Cash Flow per Share |
0.74 | 0.57 | 0.63 | 0.76 | |
Free Cash Flow |
368.00 | 284.00 | 315.00 | 379.00 | |
Capital Expenditures |
(261.00) | (276.00) | (262.00) | (238.00) | |
| Other line items | |||||
Cash ROIC |
3.26% | 2.56% | 2.88% | 3.43% | |
Accounts Receivable Turnover |
4.89 | 5.16 | 4.42 | 4.45 | |
Accounts Payable Turnover |
6.77 | 6.39 | 6.27 | 5.64 | |
Inventory Turnover |
1.24 | 1.28 | 1.33 | 1.30 | |
Average Days of Payables |
62.13 | 63.30 | 61.75 | 69.55 | |
Days of Inventory on Hand |
301.46 | 298.78 | 285.00 | 288.12 | |
Tax Rate |
(3.25) | 0.04 | 0.23 | 0.20 | |
Research and Development Expense of Revenue |
7.75% | 7.80% | 7.58% | 7.39% | |
Selling, General and Administrative Expense of Revenue |
30.32% | 30.33% | 30.04% | 30.26% | |
Share Based Compensation of Revenue |
1.46% | 1.44% | 1.51% | 1.47% | |
Interest Coverage |
1.07 | 0.07 | 0.24 | 0.33 | |
Operating CF/Net income |
17.47 | (2.41) | (2.38) | (3.10) | |
Depreciation/Fixed assets |
0.48 | 0.48 | 0.50 | 0.49 | |
Capex/Depreciation |
(0.39) | (0.41) | (0.38) | (0.34) | |
Revenue per Share |
9.24 | 9.50 | 9.83 | 10.05 | |
Operating CF per Share |
1.27 | 1.13 | 1.16 | 1.24 | |
Capex per Share |
(0.53) | (0.56) | (0.53) | (0.48) | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.05 |
Columns are period end dates